Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pimicotinib + omeprazole
- Development stage
- Unknown
- Lead developer
- Abbisko Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABSK021 + omeprazole is a drug combination primarily utilized in clinical pharmacology studies to evaluate the impact of gastric acid suppression on the pharmacokinetics of pimicotinib (ABSK021). Pimicotinib is a potent and highly selective small-molecule inhibitor of the colony-stimulating factor 1 receptor (CSF-1R), developed by Abbisko Therapeutics for the treatment of tenosynovial giant cell tumor (TGCT) and other solid tumors. Omeprazole is a proton pump inhibitor (PPI) that increases gastric pH by inhibiting the H+/K+-ATPase enzyme. Because the solubility and absorption of many tyrosine kinase inhibitors are pH-dependent, co-administration with omeprazole is studied to determine if elevated gastric pH significantly alters the systemic exposure of pimicotinib, which informs dosing recommendations for patients concurrently using acid-reducing agents.
- Brand names
- Prilosec
- Other names
- ABSK021 + omeprazolepimicotinib + omeprazole
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on pimicotinib + omeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pimicotinib + omeprazole.